Abstract 【Objective】To explore the significance and relationship of pulmonary fibrosis with miR-21 and SP-A,SP-D in serum and MRC-5 cells of pulmonary fibrosis patients.【Methods】From October 2020 to June 2021,30 patients with Pulmonary fibrosis (the pulmonary fibrosis group) and 30 healthy volunteers (the healthy group) were recruited in our hospital for the study. The expression levels of miR-21,SP-A,and SP-D in serum of the two groups were detected and compared. Meanwhile,MRC-5 cells were divided into an empty virus control group (transfected with meaningless miRNA lentivirus),a miR-21 overexpression group (transfected with miR-21 mimetic vector),and a miR-21 silencing group (transfected with inhibitor lentivirus vector). The expression levels of miR-21,SP-A,and SP-D mRNA in MRC-5 cells in each group were measured and compared. 【Results】 Serum levels of miR-21,SP-A and SP-D in the pulmonary fibrosis group were higher than those in the healthy group (P<0.05). In the cell experiment,levels of SP-A and SP-D in the miR-21 overexpression group were significantly higher than those in the empty virus control group (P<0.05). After silencing miR-21,the levels of SP-A and SP-D were significantly lower than those of the empty virus group (P<0.05). 【Conclusion】miR-21,SP-A and SP-D can be used as biomarkers of pulmonary fibrosis. And the expression of SP-A and SP-D decreases by inhibiting miR-21,which can inhibit the occurrence and development of pulmonary fibrosis.
LI Zhi,CHEN Jun-yi. Expression and Significance of miR-21,SP-A and SP-D in Serum and MRC-5 Cells of Patients with Pulmonary Fibrosis[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(8): 1143-1145.
[1] 房莉颖,吴林. 核心蛋白聚糖在特发性肺纤维化患者血清中的表达及其意义[J].医学临床研究,2021,38(3):437. [2] 魏文婕. 转化生长因子β1与肺纤维化及相关药物的研究进展[J].医学临床研究,2021,38(10):1441-1444. [3] HASTINGS R H. Monitoring alveolar epithelial function in acute lung injury [J].J Clin Monit Comput,2000,16(5-6):385-392. [4] SONG J W,DO K H,JANG S J,et al. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathicpulmonary fibrosis[J].Chest,2013,143(5): 1422-1429. [5] LU T X,ROTHENBERG M E. MicroRNA[J].J Allergy Clin Immunol,2018,141(4):1202-1207. [6] OHSHIMO S,ISHIKAWA N,HORIMASU Y,et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis [J].Respir Med,2014,108(7):1031-1039. [7] 陈俊伊,王懿春. 微小RNA-21和转化生长因子β1在急性呼吸窘迫综合征大鼠肺纤维化组织中的表达变化[J].中华危重症医学杂志(电子版),2016,9(4):234-239. [8] WHITSETT J A,WERT S E,WEAVER T E. Diseases of pulmonary surfactant homeostasis[J].Annu Rev Pathol,2015,10(4):371-393. [9] CARDENAS C L,KAMINSKI N,KASS D J. Micromanaging microRNAs: using murine models to study microRNAs in lung fibrosis[J].Drug Discov Today ,2013,10(3):e145. [10] HOUDA B,WEI G,PIERCE B M,et al. The miR-200 family and its targets regulate type Ⅱ cell differentiation in human fetal lung[J].J Biol Chem,2015,290(37):22409-22422. [11] WEI G,BENLHABIB H,MENDELSON C R. The MicroRNA 29 family promotes type II cell differentiation in developing lung[J].Mol Cell Biol,2016,36(16):2141. [12] KIM K,SHIN D,LEE G,et al. Loss of SP-A in the lung exacerbates pulmonary fibrosis[J].Int J Mol Sci,2022,23(10):5292.
[1]
. [J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(2): 272-274.
2023, Vol. 40 
